Lumos Diagnostics Holdings Limited
LDX.ASXHealth Care
Development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests.
Market Data
$0.115
+0.0%$106.9M
-100000.0x
$-0.017
0.00%
-0.4%
Latest Earnings
Appendix 4D and Half Year Report
27 February 2026
Lumos Diagnostics (LDX) reported 1H FY2026 revenue of US$6.12M, down 2.9% on the prior corresponding period, as a decline in contract services revenue (down 19% to US$4.44M due to Hologic project timeline extension) was largely offset by FebriDx® product sales doubling to US$1.68M. The net loss widened 74% to US$4.88M, primarily driven by non-cash items including a US$1.40M share-based payments expense and higher finance costs, while the adjusted EBITDA loss was a more modest US$1.38M. Critically, the auditor has flagged a going concern uncertainty, though management points to the imminent FDA CLIA Waiver decision for FebriDx® (expected by 31 March 2026) and the associated US$5.0M Phase Scientific milestone payment as key near-term liquidity catalysts. Key points: FebriDx® product revenue doubled to US$1.68M (up 100% pcp), driven by US commercial launch and milestone payments from Phase Scientific and BARDA; Operating cash flow turned strongly positive at US$0.76M (vs. outflow of US$6.32M in pcp), supported by US$2.45M in BARDA government grant receipts; Full US Medicare reimbursement recognition achieved across all seven MAC jurisdictions in November 2025, a critical foundation for FebriDx® US market penetration
Recent Announcements
Appendix 4D and Half Year Report
Lumos Diagnostics (LDX) reported 1H FY2026 revenue of US$6.12M, down 2.9% on the prior corresponding period, as a decline in contract services revenue (down 19% to US$4.44M due to Hologic project timeline extension) was largely offset by FebriDx® product sales doubling to US$1.68M. The net loss widened 74% to US$4.88M, primarily driven by non-cash items including a US$1.40M share-based payments expense and higher finance costs, while the adjusted EBITDA loss was a more modest US$1.38M. Critically, the auditor has flagged a going concern uncertainty, though management points to the imminent FDA CLIA Waiver decision for FebriDx® (expected by 31 March 2026) and the associated US$5.0M Phase Scientific milestone payment as key near-term liquidity catalysts. Key points: FebriDx® product revenue doubled to US$1.68M (up 100% pcp), driven by US commercial launch and milestone payments from Phase Scientific and BARDA; Operating cash flow turned strongly positive at US$0.76M (vs. outflow of US$6.32M in pcp), supported by US$2.45M in BARDA government grant receipts; Full US Medicare reimbursement recognition achieved across all seven MAC jurisdictions in November 2025, a critical foundation for FebriDx® US market penetration
Get real-time alerts for LDX
Receive AI-powered earnings summaries and instant notifications when Lumos Diagnostics Holdings Limited releases results.
Register Free